- Home
- DVAX vs GBX Comparison
DVAX vs GBX Comparison
Compare DVAX & GBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- GBX
- Stock Information
- Founded
- DVAX 1996
- GBX 1974
- Country
- DVAX United States
- GBX United States
- Employees
- DVAX N/A
- GBX N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- GBX Railroads
- Sector
- DVAX Health Care
- GBX Industrials
- Exchange
- DVAX Nasdaq
- GBX Nasdaq
- Market Cap
- DVAX 1.3B
- GBX 1.4B
- IPO Year
- DVAX 2004
- GBX N/A
- Fundamental
- Price
- DVAX $9.70
- GBX $46.26
- Analyst Decision
- DVAX Buy
- GBX Hold
- Analyst Count
- DVAX 4
- GBX 2
- Target Price
- DVAX $26.50
- GBX $59.50
- AVG Volume (30 Days)
- DVAX 1.9M
- GBX 250.4K
- Earning Date
- DVAX 11-06-2025
- GBX 10-22-2025
- Dividend Yield
- DVAX N/A
- GBX 2.76%
- EPS Growth
- DVAX N/A
- GBX 88.14
- EPS
- DVAX N/A
- GBX 7.10
- Revenue
- DVAX $316,268,000.00
- GBX $3,533,700,000.00
- Revenue This Year
- DVAX $23.23
- GBX N/A
- Revenue Next Year
- DVAX $16.57
- GBX N/A
- P/E Ratio
- DVAX N/A
- GBX $6.52
- Revenue Growth
- DVAX 26.66
- GBX 0.70
- 52 Week Low
- DVAX $9.20
- GBX $37.77
- 52 Week High
- DVAX $14.63
- GBX $71.06
- Technical
- Relative Strength Index (RSI)
- DVAX 41.54
- GBX 47.99
- Support Level
- DVAX $9.20
- GBX $45.84
- Resistance Level
- DVAX $9.94
- GBX $47.27
- Average True Range (ATR)
- DVAX 0.30
- GBX 1.01
- MACD
- DVAX -0.05
- GBX 0.02
- Stochastic Oscillator
- DVAX 40.65
- GBX 38.67
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.